$PBLS

RA CAPITAL MANAGEMENT, L.P. purchased $423.8M of PBLS (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 21,188,750 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at $20.00 ($423.78M total) across 2 trades on 2026-06-11.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jun 15, 2026, 10:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 11:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PBLS
Bullish
medium confidence
Mentioned
$PBLS
Relevance
10/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PBLSBullishLow
01

Why it matters

A large open-market purchase by RA Capital Management (10% owner/director role) is a sentiment signal, but it does not provide new clinical, regulatory, or financial performance information.

02

Market read

Traders may treat the disclosure as a modest bullish signal, but it is unlikely to drive a sustained repricing without accompanying fundamental updates.

03

What to watch

Check whether the fund’s indirect holdings are tied to broader strategy, and whether there are concurrent sell transactions or financing/lockup constraints not shown in this excerpt.

Relevance 10/10Novelty 6/10Timing: SEC Form 4 filed 2026-06-15 for trades dated 2026-06-11

Background

The article is an SEC Form 4 insider transaction disclosure for Parabilis Medicines, Inc. (PBLS).

Company-level read

Ticker impact

$PBLSBullishMedium confidence
Context

RA Capital Management, L.P. filed an SEC Form 4 showing an indirect open-market purchase of 21,188,750 PBLS shares at $20.00.

Expected impact

Near-term support possible if the market interprets the buy as confidence; magnitude likely limited because it’s an ownership disclosure rather than new operating information.

Evidence & confidence

The filing is primary-source and sizable, but Form 4 buys often reflect planned allocations/portfolio actions and do not change PBLS fundamentals by themselves.

Market effects

Minimal sector read-through; this is company-specific ownership activity in a single issuer.

None indicated.

None indicated.

Counterpoint

The buy may be part of routine portfolio rebalancing or indirect structuring rather than a new view on near-term fundamentals; without a 10b5-1 plan, it still may reflect pre-existing intent.

Key entities

  • Parabilis Medicines, Inc.

    Subject of the Form 4 insider transaction; ticker PBLS.

  • RA Capital Management, L.P.

    10% owner/director role reporting an indirect open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PBLSMed

Parabilis Medicines, Inc. (PBLS): Results of Operations and Financial Condition

Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ck0001657677-ex99_1.htm EX-99.1 EX-99.1 Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in

$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.

$PBLSMedAI 9/10

Parabilis Medicines raises record $670 million in biotech IPO

Parabilis Medicines priced its Nasdaq IPO at $20/share, raising $670 million by selling 33.5 million shares, above its $17–$19 range, according to the company. Trading under “PBLS” starts Wednesday. Underwriters can buy 5.025 million more shares. A related private placement with Regeneron bought 4.17 million shares at $18, adding ~$75 million. Total raised is ~$745 million; valuation is ~$2.4 billion.

$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $6.1M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 246,568 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $24.85 ($24.69–$24.87, $6.13M total) across 3 trades over 2026-08-13 to 2026-08-17. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Divisadero Street Capital, LLC (10% owner), Divisadero Street Partners, L.P. (10% owner) and Zolezzi William (10% owner).